Federal food and drug officials said Friday that they plan to fill in current CBD research gaps with “real world data” — but industry advocates are frustrated that regulators haven’t done enough to clear up the rules, which has caused supply-chain bottlenecks while leaving consumers to navigate an increasing field of unregulated products.
CBD businesses looking for regulatory clues from U.S. food and drug regulators were watching closely in mid-November, when the U.S. Food and Drug Administration reassured the industry and the public that the science of CBD and other cannabinoids.
U.S. health officials are asking for research about how hemp-derived cannabinoids and other plant-derived treatments affect chronic pain. The review will focus on: The benefit of cannabinoids for adults with chronic pain, including specific efficacy outcomes. The harm of cannabinoids in adults with chronic pain, including adverse effects. Cannabinoid delivery. Synthetic cannabinoids. Submissions are due by Jan. […]
